Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
D000477:Alkylating Agents / Q000627:therapeutic use; D000505:Alopecia / Q000139:chemically induced; D004341:Drug Evaluation; D004351:Drug Resistance; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
D000477:Alkylating Agents; D005047:Etoposide; D011034:Podophyllotoxin